Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis (TARGET)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT02053909

Recruitment Status : Recruiting

First Posted : February 4, 2014

Last Update Posted : July 9, 2019

See Contacts and Locations

Sponsor:

Collaborators:

AstraZeneca

Ottawa Heart Institute Research Corporation

Information provided by (Responsible Party):

Dr. Alexander Kulik, Boca Raton Regional Hospital

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Recruiting
Estimated Primary Completion Date :	August 2022
Estimated Study Completion Date :	August 2023

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Kulik A, Abreu AM, Boronat V, Kouchoukos NT, Ruel M. Impact of ticagrelor versus aspirin on graft patency after CABG: Rationale and design of the TARGET (ticagrelor antiplatelet therapy to reduce graft events and thrombosis) randomized controlled trial (NCT02053909). Contemp Clin Trials. 2018 May;68:45-51. doi: 10.1016/j.cct.2018.03.008. Epub 2018 Mar 15.

To Top